The stock of BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) decreased by -$0.12 on Wednesday to $6.97, down -1.69 percent. The last five days have seen an average of 1,301,368 shares of common stock traded. 3 times new highs were reached in the current year, with a fall of -$4.47. The average number of shares traded over the last 20 days was 2,417,662, while the average volume over the last 50 days totaled 2,510,765.
BCRX stock dropped 0.00% since last month. On 08/08/23, the company’s shares reached a one-month low of $6.62. The stock touched a high of $14.50 on 01/06/23, after rallying from a low of $6.62 in 52 weeks. The price of BCRX stock has declined by -39.29% or -$4.47 this year, reaching a new high 3 times. Still, the stock price is down -51.93% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
BCRX stock investors should be aware that BioCryst Pharmaceuticals Inc. (BCRX) stock had its last reported insider trading activity 76 days ago on Jun 15. On Jun 15, Director SANDERS MACHELLE sold 4,000 shares at $7.98 each. This transaction resulted in the insider making $31,920. On Jun 14, Hutson Nancy J sold 12,866 shares at a price of US$8.04. After the transaction, the insider now owns 81,818 shares. Chief R&D Officer Thackray Helen M. had earlier sold 7,000 shares on Apr 03 for $8.29 a share. The transaction was completed for $58,030.
Financial Health
For the three months ended June 29, BioCryst Pharmaceuticals Inc.’s quick ratio was 5.20, while its current ratio was 5.50, indicating its ability to pay off its debt. As far as profitability goes, gross margin for the trailing twelve months is 97.40% percent. BioCryst Pharmaceuticals Inc.’s EBITDA margin for the year ended June 29 was -54.28%, whereas its operating margin stood at -46.30% for the same period. Based on annual data, it had gross profit of $264.42 million and revenue of $270.83 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. BCRX’s return on assets (ROA) during the last 12 months has been -45.20%. There was a -34.50% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was 77.40%.
Earnings Surprise
According to BioCryst Pharmaceuticals Inc.’s quarterly financial report for the quarter that ended June 29. A higher net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $82.49 million, while revenues rose by 20.56% to $68.78 million. It was predicted that BioCryst Pharmaceuticals Inc.’s quarterly earnings would be -$0.4, but it ended up being -$0.23, beating the consensus by -73.90%. EBITDA was -$23.13 million for the quarter. At the end of BioCryst Pharmaceuticals Inc.’s most recent quarter ended June 29, its liabilities totaled 918.6 million, while its total debt was $827.63 million. Equity owned by shareholders amounts to $189.49 million.
Technical Picture
Here’s a quick look at BioCryst Pharmaceuticals Inc.’s (BCRX) price momentum from a technical perspective. As of 29 August, the RSI 9-day stood at 43.58%, suggesting the stock is Neutral, with a 40.20% historical volatility rate.
The stochastic %K and %D were 45.54% and 54.84% respectively, while the average true range (ATR) was 0.28. Based on the 14-day stochastic reading of 31.98%, the RSI (14) reading is 45.61%. On the 9-day MACD Oscillator, the stock is at -0.08, and the 14-day reading is at -0.01.
Analyst Ratings
In its most recent analyst report, Jefferies raised its rating on BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) to a Buy. Prior to this, analysts firm rated the stock as a Hold. Analysts have assigned BioCryst Pharmaceuticals Inc. (BCRX) an Overweight rating. BCRX is a stock that is recommended for selling by 0 brokerage firms, while 3 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 8 others recommend it as a buy.
What is BCRX’s price target for the next 12 months?
The current consensus forecast for the stock is between $8.00 and $30.00, with a median target price of $11.50. In analyzing these forecasts, the average price target given by analysts for BioCryst Pharmaceuticals Inc. (BCRX) is $15.10.
